Ratings Qiagen N.V.

Equities

QGEN

NL0015001WM6

Market Closed - Nyse 04:00:02 2024-04-17 pm EDT Pre-market 09:17:46 am
39.23 USD -0.23% Intraday chart for Qiagen N.V. 39.32 +0.23%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • According to Refinitiv, the company's ESG score for its industry is good.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company benefits from high valuations in earnings multiples.
  • With an enterprise value anticipated at 4.48 times the sales for the current fiscal year, the company turns out to be overvalued.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
-12.38% 8.68B
A
-1.78% 41.36B
B
+43.68% 41.3B
A
+4.01% 39.61B
B-
-15.14% 25.62B
C
+3.16% 24.09B
B-
-24.08% 18.38B
B
+24.76% 11.85B
C+
-2.67% 11.82B
C+
+7.01% 11.07B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes